Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Andera Partners

Q2 2026 · 13F-HR

Andera Partnersholdings as filed

Filed 2026-07-22 · accession 0001757283-26-000015

$206.5M
Reported value
8
Positions
2026-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
G52441105KMTSKESTRA MED TECHNOLOGIES LTD$69.4M33.6%2,728,679CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$42.9M20.8%1,591,917CommonSOLE
05348Y105AVLNAVALYN PHARMACEUTICALS INC$30.6M14.8%929,824CommonSOLE
00860C102AGMBAGOMAB THERAPEUTICS NV$20.0M9.67%1,538,702CommonSOLE
30054Y107EVMNEVOMMUNE INC$18.5M8.96%1,391,990CommonSOLE
46124U107IVAINVENTIVA SA$13.7M6.65%3,633,181CommonSOLE
00370M103ABVXABIVAX SA$10.4M5.04%78,125CommonSOLE
B6S7WD106NYXHNYXOAH S A$882,2760.43%522,057CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.